VBIV News and Press, VBI Vaccines Inc. From 11/14/23

2023-11-14 16:43:56 ET More on VBI Vaccines VBI Vaccines gains after Phase 2 data for Hep B candidate Seeking Alpha’s Quant Rating on VBI Vaccines Historical earnings data for VBI Vaccines Financial information for VBI Vaccines For further deta...

PreHevbrio (Hepatitis B Vaccine [Recombinant]) global net revenue increased 52% quarter-over-quarter from Q2 to Q3 2023 Continued execution across earlier-stage pipeline, including: Initiation of Phase 2b study of VBI-1901 in recurrent glioblastoma (GBM) patients Interim Phase 1 data ...

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

VBI Vaccines Inc. (VBIV) is expected to report $-0.14 for Q3 2023

2023-11-03 15:23:43 ET More on XBI and IBB Biopharma Bounce-Back: From Policy Pains To Profitable Plains IBB: The Illness Of Idiosyncratic Risk Jefferies is bullish on XBI at around $70 for year-end and first quarter 2024 returns Citi turns cautious on pharma...

Preclinical data suggests novel mRNA-launched eVLPs (“MLE”) generate significantly enhanced B-cell and T-cell responses compared to mRNA-expression of antigens alone In addition to immunologic benefits, new MLE technology enables manufacturing of particulate vaccines on an accel...

First clinical data from a pan-coronavirus vaccine candidate Elicited high and sustained neutralizing responses against a panel of COVID-19 variants, including Wuhan, Delta, Beta, Omicron BA.5, as well as multiple animal coronaviruses including bat and pangolin variants Durability of prot...

Multi-center, randomized, controlled, open-label study to enroll up to 60 patients with first recurrent GBM FDA has granted both Fast Track Designation and Orphan Drug Designation to VBI-1901 in the recurrent setting, following encouraging Phase 1/2a study results Interim data ana...

BRII-179 (VBI-2601) as an add-on therapy to standard of care PEG-IFNα increases HBsAg loss rate at the end of treatment and 12 weeks follow up Significantly increased seroconversion rate is strongly associated with BRII-179 (VBI-2601) treatment and correlates with the increased rate of...

2023-09-06 07:33:44 ET More on VBI Vaccines VBI Vaccines slides on discounted stock and warrants offering VBI Vaccines down 3% after hours on public offering VBI Vaccines: Recent Updates Have Fortified My Long-Term Outlook For further details see: ...